Business Monitor International


New Zealand Pharmaceuticals & Healthcare Report

Published 05 February 2014

  • 88 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
New Zealand Pharmaceuticals & Healthcare Report

BMI View: We highlight that the attractiveness of New Zealand's pharmaceutical market is highly dependent on the decisions made by the Pharmaceutical Management Agency (PHARMAC). While the tightly controlled PHARMAC will ensure the country does not overspend on pharmaceuticals, the drug lag remains a downside risk for innovative firms looking to launch products in the country, negatively impacting patients.

Headline Expenditure Forecasts

  • Pharmaceuticals : NZD1.42bn (US$1.17bn) in 2013 to NZD1.46bn (US$1.10bn) in 2014; +2.8% in local currency terms.

  • Healthcare: NZD22.00bn (US$18.04bn) in 2013 to NZD23.03bn (US$17.27bn) in 2014; +4.7% in local currency terms.

Risk/Reward Rating: New Zealand's score of 52.8 out of 100 is dragged down by a low industry rewards score, due to its small and relatively low-growth potential market, and a low industry risks score because of its regulatory processes. In terms of Rewards, New Zealand is rated highly owing to a stable economic and political environment and developed regulatory regimen. The country is ranked ninth out of the 19 markets in the Asia Pacific RRR matrix.

Key Trends & Developments

In December 2013, PHARMAC announced that the rotavirus and varicella vaccines will be added to the national immunisation schedule, along with improved versions of previously funded vaccines such as the pneumococcal vaccine Prevenar 13. The changes to the national immunisation schedule will come into place from July 1 2014.

Figures released in December 2013 by the Medical Council showed the proportion of New Zealand doctors remaining in the country after they had graduated had fallen. Although the statistics showed the number of active doctors was up by 2.5% in 2012, the rate of new doctors entering the workforce had slowed. Numbers jumped from 14,333 in 2011 to 14,686 in 2012, but that was compared with an increase of 3.2% in 2011 and 3.5% in 2010. On average, 84% New Zealand graduates are retained for two years after they graduate....

Table of Contents

BMI Industry View
7
SWOT
9
Political
10
Economic
11
Business Environment
13
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: New Zealand Pharmaceutical Sales, Historical Data and Forecasts
16
Healthcare Market Forecast
17
Table: New Zealand Healthcare Expenditure Trends, Historical Data & Forecast
18
Table: New Zealand Government Healthcare Expenditure Trends, Historical Data and Forecasts
18
Table: New Zealand Private Healthcare Expenditure Trends, Historical Data and Forecasts
19
Prescription Drug Market Forecast
20
Table: New Zealand Prescription Drug Market Indicators, Historical Data and Forecasts
21
Patented Drug Market Forecast
22
Table: New Zealand Patented Drug Market Indicators, Historical Data and Forecasts
22
Generic Drug Market Forecast
23
Table: New Zealand Generics Drug Market Indicators, Historical Data and Forecasts
24
OTC Medicine Market Forecast
25
Table: New Zealand Over-The-Counter (OTC) Medicine Market Indicators, Historical Data and Forecasts
25
Pharmaceutical Trade Forecast
26
Table: New Zealand Pharmaceutical Trade Data And Forecasts (US$mn)
27
Table: New Zealand Pharmaceutical Trade Data And Forecasts (NZDmn)
27
Other Healthcare Data
28
Key Risks To BMI's Forecast Scenario
28
Macroeconomic Forecasts
30
Economic Analysis
30
Reliance On External Funding Returning After Earlier Declines
31
Housing Market At Risk As Longer End Rates Rise
32
Dairy Sector Performance Vital Component Of Export Receipts
33
Table: New Zealand - Economic Activity
35
Industry Risk Reward Ratings
36
Asia Pacific Risk/Reward Ratings
36
New Zealand Risk/Reward Ratings
42
Rewards
42
Risks
42
Market Overview
44
Industry Trends And Developments
45
Epidemiology
45
Healthcare Sector
46
Infrastructure
49
Table: Regional Ranking of Projected Physicians, 2017
51
Table: Projected Physicians, 2012-2017
52
Table: Active Medical Practitioners, 2005-2010
52
Distribution Channels
53
Table: Pharmacybrands Stores by Company & Region, 2010
55
Research and Development (R&D)
55
Clinical Trials Sector
56
Regulatory Development
58
Regulatory Regime
58
Intellectual Property Regime
58
Pricing & Reimbursement
59
Table: Leading Therapeutic Groups By PHARMAC Expenditure (NZDmn), 2005-2010
63
Table: Top 20 Medicines By Ex-Manufacturer Cost To PHARMAC In The Year Ending June 2010 (NZDmn)
64
Table: Top 20 Medicines Reimbursed By PHARMAC According To Prescription Numbers In The Year Ending June 2010
65
Recent Regulatory Developments
65
Competitive Landscape
68
Table: Licensed Medicine Manufacturing Sites
68
Company Profile
71
Douglas Pharmaceuticals
71
New Zealand Pharmaceuticals
74
Demographic Forecast
77
Table: New Zealand's Population By Age Group, 1990-2020 ('000)
78
Table: New Zealand's Population By Age Group, 1990-2020 (% of total)
79
Table: New Zealand's Key Population Ratios, 1990-2020
80
Table: New Zealand's Rural And Urban Population, 1990-2020
80
Glossary
81
Methodology
83
Pharmaceutical Expenditure Forecast Model
83
Healthcare Expenditure Forecast Model
83
Notes On Methodology
84
Risk/Reward Ratings Methodology
85
Ratings Overview
86
Table: Pharmaceutical Risk/Reward Ratings Indicators
86
Indicator Weightings
87

The New Zealand Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's New Zealand Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the New Zealand pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for New Zealand to test other views - a key input for successful budgeting and strategic business planning in the New Zealand pharmaceutical and healthcare market.
  • Target business opportunities and risks in the New Zealand pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in New Zealand.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc